![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: WDR17 |
Gene summary for WDR17 |
![]() |
Gene information | Species | Human | Gene symbol | WDR17 | Gene ID | 116966 |
Gene name | WD repeat domain 17 | |
Gene Alias | WDR17 | |
Cytomap | 4q34.2 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q8IZU2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
116966 | WDR17 | HCC1 | Human | Liver | HCC | 5.09e-09 | 8.86e-01 | 0.5336 |
116966 | WDR17 | HCC2 | Human | Liver | HCC | 1.41e-14 | 1.01e+00 | 0.5341 |
116966 | WDR17 | HCC5 | Human | Liver | HCC | 3.01e-14 | 8.14e-01 | 0.4932 |
116966 | WDR17 | HTA12-23-1 | Human | Pancreas | PDAC | 1.27e-03 | 6.03e-01 | 0.3405 |
116966 | WDR17 | HTA12-25-1 | Human | Pancreas | PDAC | 3.33e-03 | 4.07e-01 | 0.313 |
116966 | WDR17 | HTA12-26-1 | Human | Pancreas | PDAC | 2.63e-13 | 7.33e-01 | 0.3728 |
116966 | WDR17 | HTA12-29-1 | Human | Pancreas | PDAC | 9.44e-28 | 6.40e-01 | 0.3722 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WDR17 | SNV | Missense_Mutation | c.3760N>A | p.Gly1254Arg | p.G1254R | Q8IZU2 | protein_coding | tolerated(0.32) | benign(0.013) | TCGA-BR-8361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
WDR17 | SNV | Missense_Mutation | c.1416N>G | p.Ile472Met | p.I472M | Q8IZU2 | protein_coding | deleterious(0.01) | possibly_damaging(0.502) | TCGA-BR-8487-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
WDR17 | SNV | Missense_Mutation | c.1603N>A | p.Asp535Asn | p.D535N | Q8IZU2 | protein_coding | tolerated(0.11) | probably_damaging(0.999) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
WDR17 | SNV | Missense_Mutation | c.2495N>A | p.Ile832Asn | p.I832N | Q8IZU2 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-BR-A453-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
WDR17 | SNV | Missense_Mutation | rs770701279 | c.3913N>T | p.Ala1305Ser | p.A1305S | Q8IZU2 | protein_coding | tolerated(0.1) | probably_damaging(0.993) | TCGA-CD-8536-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | epirubicin | CR |
WDR17 | SNV | Missense_Mutation | c.2785T>A | p.Ser929Thr | p.S929T | Q8IZU2 | protein_coding | tolerated(0.34) | benign(0.006) | TCGA-D7-A4YU-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | SD | |
WDR17 | SNV | Missense_Mutation | rs768177361 | c.2171G>A | p.Arg724Lys | p.R724K | Q8IZU2 | protein_coding | tolerated(0.37) | benign(0.005) | TCGA-D7-A6F2-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
WDR17 | SNV | Missense_Mutation | c.1162A>G | p.Arg388Gly | p.R388G | Q8IZU2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-HU-A4G8-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
WDR17 | SNV | Missense_Mutation | novel | c.854T>A | p.Ile285Lys | p.I285K | Q8IZU2 | protein_coding | deleterious(0) | benign(0.312) | TCGA-KB-A93H-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WDR17 | SNV | Missense_Mutation | novel | c.3062N>A | p.Cys1021Tyr | p.C1021Y | Q8IZU2 | protein_coding | tolerated(0.1) | benign(0.101) | TCGA-MX-A5UJ-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |